get daily headlines subscribe now! today's private briefing

Article Index

biotech stocks

One of the Top Biotech Stocks to Buy Just Hit the Market

biotech stocks to buy

One of the last week's biggest IPOs, the food allergy company Aimmune Therapeutics Inc. (Nasdaq: AIMT), hit the market on Thursday, Aug. 6, and has already climbed more than 20%.

AIMT's early success underscores one of the best biotech stocks to buy that Money Morning Executive Editor Bill Patalon has been recommending all year.

Food allergies affect tens of millions around the world. And the companies that treat these people offer some of the best profit opportunities among biotech stocks today...

This Bioscience Company Has "Nearly Limitless" Income Potential


Medical device companies can be profit-making machines - one manufacturer of magnetic resonance imaging (MRI) machines and other high-tech products is up more than 250% over the past 12 months, for instance.

Most of them make their living by staying on the leading edge of innovation, producing some of the coolest gadgets you can imagine.

And, even better, they can deliver some of the most impressive gains in the bioscience industry to their shareholders.

The good performance of these manufacturers gives you some idea of the potential we're dealing with here.

Just look at these soaring share prices...

This Cannabis Biotech Leader Helped Us Beat the Market by More Than 620%


Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.

Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.

And if you missed this stock last year - no worries. We'll start you now as it continues its run - a run that took off while "popular" medical marijuana stocks cratered.

Here's how we'll do it...

Now's Our Chance to Play This Month's Best IPO

IPO Editor's Note: Normally this intelligence would go to paid-up members of Bill's Private Briefing, but this debut is going to be so big, and the medicine so important, that he wanted to give everyone a chance to tap this $21 billion market. The shares start trading on Thursday, Aug. 6, so there's some time to […]

Read More…

Why Pharmaceutical Stocks Are Crushing the Market [Chart]

Biotech Investing

Pharmaceutical stocks have crushed the broader markets in 2015.

The S&P Pharmaceuticals Select Industry Index has climbed 20.9% year to date. In the last 12 months, the index has climbed 42.5%.

Here's how that compares to the broader markets...

2015 Top Stock Picks Moving Against Stock Market Plunge

2015 top stock picks

Many of our 2015 top stock picks were crushed by the recent downturn in the broader markets - brought on by uncertainty in China and Europe.

But one stock pick has moved against the crashing financial markets: Novavax Inc. (Nasdaq: NVAX).

NVAX stock has doubled on the year. Here's what you need to know...

Why Trillium (Nasdaq: TRIL) Stock Is Today's Top Biotech Buy

TRIL stock

Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.

You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer.

Here's how the treatment works, and how it could make TRIL stock the next great biotech blockbuster...

Google's Larry Page and Sergey Brin Plan to Cure Aging with Biotech Venture

Larry Page and Sergey Brin

Google Inc.'s (Nasdaq: GOOG, GOOGL) Larry Page and Sergey Brin have taken anti-aging to a whole new level.

In 2013, Google founded the biotech company Calico along with Apple Inc. (Nasdaq: AAPL) Chairman Arthur Levinson.

Rather than focusing on diseases, Calico was founded to cure aging. According to Page, expanding the human life span by as much as 100 years is the company's goal.

Thanks to new breakthroughs, they may be closer than you think...

The Next Great Blockbuster Biotech Stock to Buy Now

biotech stock

Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.

That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.

Now, Money Morning Biotech Investing Specialist Ernie Tremblay has found a new biotech stock to buy that could be the next cancer blockbuster...

These Promising Cancer Therapies Are a Biotech "Triple Play"


On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.

Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.

And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.

It's clear that investors can do very well with the right cancer drug.

But there, of course, is the rub: Finding the right cancer drug is not so easy.

I'm about to show you three companies - all sound investments - running strong in the race to fight this scourge, and the one that could very well take the prize...

The Best Biotech ETF to Buy in 2015

Biotech etf

Biotech stocks have seriously outperformed the markets in 2015, and our favorite biotech ETF has been one of the biggest winners.

In the last year, the Nasdaq Biotechnology Index has soared 48.3%. The Dow and S&P 500 are up just 7.3% and 8.6% in that time.

Here's our favorite biotech ETF to buy now...

How to Play Organovo (NYSE: ONVO) Stock After Earnings

ONVO stock

Organovo Holdings Inc. (NYSE: ONVO) stock is up 12.7% this week after the company reported quarterly and fiscal year earnings on Tuesday.

For the quarter ending March 31, ONVO reported an earnings per share (EPS) loss of $0.10. That was below the consensus estimate of a $0.09 loss.

Here's what else investors need to know about ONVO stock now...

Top Biotechnology Companies Profiting from ASCO 2015

biotechnology companies

The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago this week.

More than 30,000 people attend the event, which features more than 4,000 presentations from some of the top biotechnology companies in the world.

For investors, this provides us an in-depth look at some of the world’s best biotechnology companies to invest in.

Why Organovo Stock Is a Top Biotech Stock to Buy in 2015

Organovo stock

One of our favorite biotech stocks of 2015, Organovo stock, has climbed 41% since the end of March. And that's just the start for this revolutionary biotech investment.

You see, Organovo Holdings Inc. (NYSEMKT: ONVO) is part of one of the most exciting biotech industries on the market. It's called 3D bioprinting, and the applications are huge.

Here's a closer look at the 3D bioprinting market and why it's providing us with such a great investment opportunity.

"21st Century Cures" Could Revolutionize Biotech

Medicine Pills Stacked Like Increasing Graph on Newly Designed U.S. One Hundred Dollar Bills.

No one is thrilled with the way new drugs and medical devices come to market in the U.S. - not the biotech and pharmaceutical companies, not the regulators at the Food and Drug Administration (FDA) or National Institutes of Health (NIH), not physicians, and certainly not patients desperately in need of new therapies.

The process is hugely expensive and incredibly slow. According to the Tuft's Center for the Study of Drug Development, the average cost of bringing a new prescription drug from lab to market now tops $2.5 billion and takes more than 10 years.

That can make for a real thrill ride where investors are concerned, as share price for a pre-profit biotech can rise and fall dramatically and unpredictably with every related data release, financial report, news item, or regulatory hiccup over an entire decade, making long-term investment a crapshoot, at best.

But new regulations on the table could change everything for biotech investors and critically ill patients...